Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
16 search results for:

Lesinurad 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 14-08-2018 | Gout | Article

    Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout

    Terkeltaub R et al. Rheumatology (Oxford) 2018: key245. doi: 10.1093/rheumatology/key245

  2. 29-09-2017 | Gout | News | Article

    High-dose lesinurad monotherapy ‘should not be used’ for the treatment of gout

    Results of the phase III LIGHT trial suggest that gout patients who are treated with lesinurad 400 mg experience a greater reduction in serum uric acid levels than those given placebo, but at the cost of renal-related adverse events.

    Published in:
    Rheumatology 2017; Advance online publication
  3. 04-08-2017 | Gout | Article

    Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial

    This phase III study was conducted to investigate the use of lesinurad combined with febuxostat in the treatment of tophaceous gout. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Arthritis Rheumatol . 2017;69:1903–1913. doi: 10.1002/art.40159.

  4. 03-10-2016 | Gout | Article

    Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

    This research article defines the mechanism of action of lesinurad, a novel renal urate transporter 1 inhibitor, recently approved in the USA and Europe for treatment of chronic gout. Miner JN et al. Arthritis Res Ther 2016;18:214. doi:10.1186/s13075-016-1107-x

  5. 03-10-2016 | Gout | Article

    Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

    This paper profiles lesinurad, a novel uric acid-lowering therapy for the treatment of gout. Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, et al.  Arthritis Res Ther . 2016;18:214. doi: 10.1186/s13075-016-1107-x.

  6. 03-05-2018 | Gout | Case report | Article

    Retreatment with pegloticase after a gap in therapy in patients with gout: A report of four cases

    He continues to be treated with allopurinol 300 mg and lesinurad 200 mg daily.

  7. 30-10-2017 | Gout | Editorial | Article

    Evolution or revolution in urate-lowering therapies for gout?

    Whilst combination therapy has previously been mostly empiric and based on small, open-label, non-comparative studies; the advent of lesinurad, a uricosuric medication labeled to be used in combination with xanthine oxidase inhibitors, has resulted in three double-blind combination therapy trials.

    Author:
    Fernando Pérez-Ruiz
  8. 21-06-2018 | Gout | Review | Article

    Predicting response or non-response to urate-lowering therapy in patients with gout

    The authors review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy may be modified to increase the response in the majority of patients with gout. Graham GG et al. Curr Rheumatol Rep 2018; 20: 47. doi: 10.1007/s11926-018-0760-2

  9. 21-06-2018 | Gout | Highlight | Teaser
    Journal article

    Predicting response or non-response to urate-lowering therapy in patients with gout

    The authors review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy may be modified to increase the response in the majority of patients with gout [ read more ]. Graham GG et al. Curr Rheumatol Rep 2018; 20: 47. doi: 10.1007/s11926-018-0760-2

  10. 08-05-2018 | Gout | Review | Article

    An update on the genetics of hyperuricemia and gout

    Major TJ et al. Nat Rev Rheumatol 2018; Advance online publication. doi: 10.1038/s41584-018-0004-x

  11. 20-03-2018 | Gout | Review | Article

    What is the evidence for treat-to-target serum urate in gout?

    Bursill D, Dalbeth N. Curr Rheumatol Rep 2018; 20: 11. doi: 10.1007/s11926-018-0719-3

  12. 25-08-2017 | Gout | News | Article
    approvalsWatch

    FDA backs combination treatment for gout

    A formulation containing a lower dose of 200 mg lesinurad/200 mg allopurinol will be available for patients with renal impairment.

  13. 13-02-2018 | Gout | Review | Article

    Managing gout in the patient with renal impairment

    Pascual E, Sivera F, Andrés M. Drugs Aging 2018; Advance online publication. doi: 10.1007/s40266-018-0517-7

  14. 20-04-2016 | Gout | Review | Article

    New and pipeline drugs for gout

    An expert review discussing new and pipeline drugs for acute gout including prophylactic anti-inflammatory therapies as well as urate-lowering therapies. Keenan RT & Schlesinger N. Curr Rheumatol Rep 2016;18:32. doi:10.1007/s11926-016-0579-7

  15. 27-02-2015 | Gout | Review | Article

    Current and emerging therapies for gout

    The authors review some of the newer medications, which may become the future of gout therapy, including new urate-lowering therapies and new anti-inflammatory agents. Mohammad S, Giattino SL, & Keenan RT. Curr Treat Options in Rheum 2015;1:143–155. doi:10.1007/s40674-015-0015-6

  16. 26-09-2014 | Gout | Article

    Urate-lowering therapy: current options and future prospects for elderly patients with gout

    This paper discusses the use of urate-lowering therapies in elderly patients, with a focus on the available therapeutic options and their risks and benefits in this patient population, as well as a mention of pipeline therapeutics. Stamp LK, Chapman PT.  Drugs Aging . 2014;31:777–786. doi: 10.1007/s40266-014-0214-0.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.